Shield Therapeutics PLC
LSE:STX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
Shield Therapeutics PLC
LSE:STX
|
102.2m GBP |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
993.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
298B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
239.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
246.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.1B USD |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
Shield Therapeutics PLC
Glance View
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Shield Therapeutics PLC is 48.3%, which is above its 3-year median of 41%.
Over the last 3 years, Shield Therapeutics PLC’s Gross Margin has decreased from 53.2% to 48.3%. During this period, it reached a low of 30.8% on Dec 31, 2023 and a high of 53.2% on Jun 30, 2022.
